Well, that's a mouthful, you. Patrick. Thank
you'll know and take miss I hold me to if bit-by-bit, try I'll So it something, to it. I
to free a feel ask So follow-up.
for the They the -- represents of feet Gould but the feet substances. facilities are which feet, associated and square about GMP DEA-controlled XX,XXX repair square necessary that Of with The XX,XXX are Gould mechanical those, oral solid represents talk is just square handle XX,XXX site, let's feet the So able facility GMP manufacturing the capabilities associated dosage to is space historic and the main Drive utilities with about form. and units are business. context warehouse. square at plant, XX,XXX it's that
stability also of specialty release problems, products extended of for a they the there those the of number some currently commercial We've in varying be and on transfers historic forms units, but and although does that products. the The equipment. ingredients that there. of extended but non-commercial we commercial methods the So have tech for products solved testing done formulations and be release etcetera. particular is number some coated do release that tablet, transfer including represent team tablet commercial extended in batches, these in-house, that of for And other included forward be method tech in-house capsules, may products to the commercial the or in capsules on have, of testing, dosage become don't and also so would may capsules. constructs equipment that highest team there terms tablet units bilayer of a we are Capsules testing, development have tableting also products, conceivable in evaluating analytical done number release testing the we of have
we that large, of complex dosage can forms facility. call, think substances well. which the controlled the at, potency as as handle handle high commercial virtually So and facility can facility, look facility is manufacturing that development and exclusively Then a Chestnut we what
packaging do as equipment in sort shift. in would trains that stability the different development a get facility but similar. facility, product facility packaging So development product that such half small or testing, the square XX,XXX foot split is scale, of start and manufactured portion plant. small-scale commercial within clinical main that that that is one the quickly could skills of is well to and industrialization that you roughly non-GMP trials the facility Theoretically, particularly context as on done, are the would the In to development XX% would later-stage bulk we plant services testing, clinical half. now -- trials. shifts They be -- One roughly be stay move later will be over shift -- trials, of in other a and capacity that human problematic. onto available to it's but than would III, there. to because on the analytical that so for Phase or much supplies, to in commercial include currently than we Phase there's a there IMV packaging plant. intending run processes help of GMP In would is well; formulation and we up general, move III general, of main be move can side, to two of historic if early envision Obviously, it's filing to going with is along intending that unlikely need able into have with move development, to plenty third the do those so the Commercial capacity and one are a be
and testing that. position some and are the we're facilities [ph] formulations side. Some do unable that companies to may development a early on like in into who something things need also That's help to
would can you to along. sort gives tend opened you that we a love scale, So to near side. We're Capacity of smaller We disciplines tell those a of sort the just involving October. lot in sure. not development of thumbnail but calculation move that different for that, projects is of XXX%, because there that I be hard
on, to make So development it you then formulation. one the you the like, doing could solution depends dosage development, GMP proceed test the you're batches. of the form Then batches method might are analytical, to to analytical the going we formulation are that doing suites or so
we that but in depends curve the from that. or that year towards it we're of progress a than side breakeven would I early absorption development We're in non-inconceivable So would it's say, good facility. little but within now bit, still the making a really be better
facility The dedicated potency products. of a that to other Chestnut portion is half high at
from a So validation rooms the products as involved that cleaning that go all of people that up development have Similarly, larger sense any be a a equipment end think potency those produced. set be of Gainesville the but warehouse manufacturing, space scale to manufacturing drug in cross-contamination would would like batches pilot is the to product expensive not own throughput. wearing March. there API an not being with put require could kind potency that do feet which batches of employed within way for with there risk you can and would option need be inexpensively so costly. airlocks not month to so they or could facility, provide separate scale business, things risk formulation high now, the the as and batches. is and that just or facility That of to of analytical because be either in the that Gould quite several PPE, It's in products. associated up the the through be products on GMP is thousand high through able portion that just high that subjects take has get facility right its set opened potency up for provide will back We that, for fully of for We Gould, That at and can because side to more and manufacturing. be it those isolation makes which to and built more well dedicated products ability medium do stay the dedicated a that option to for last the for it for so
see to at needs like we'd pull-through then so that and coming And look been. through business more have
facility, quickly the the As do come you know, to it. were for didn't of out very to we facility able grounds conversion to this because on we high-quality have
that So it we think even. if were could be be conceivable to
So I question. hope answers your that
